AMEH Apollo Medical

Filed: 5 May 21, 4:05pm






Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 5, 2021 (May 3, 2021)



(Exact name of registrant as specified in its charter)


(State or Other Jurisdiction(Commission File(I.R.S. Employer
of Incorporation)Number)Identification Number)


1668 S. Garfield Avenue, 2nd Floor, Alhambra, CA 91801

(Address of principal executive offices) (zip code)


(626) 282-0288

(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


 ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


 ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


 ¨Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


 ¨Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockAMEHNasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 2.02Results of Operations and Financial Condition.


On May 5, 2021, Apollo Medical Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2021. A copy of the press release and supplemental data are attached hereto as Exhibit 99.1 and 99.2, respectively, and incorporated herein by this reference.


In accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item 2.02, including Exhibit 99.1 and Exhibit 99.2 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.


Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(b) Termination of Dr. Adrian Vazquez as Chief Medical Officer


On May 3, 2021, Network Medical Management, Inc., (“NMM”), a wholly-owned subsidiary of the Company, notified the Company’s Chief Medical Officer, Adrian Vazquez, M.D. that, in accordance with that certain Employment Agreement, dated June 8, 2020, between NMM and Dr. Vazquez, his employment would be terminated effective as of the date that is thirty (30) days after the notification date. Dr. Vazquez will continue in his current position with the Company until such termination date.


Item 9.01Financial Statements and Exhibits


(d) Exhibits.


Exhibit No. Description
99.1 Press Release of Apollo Medical Holdings, Inc., dated May 5, 2021.
99.2 Supplemental Data of Apollo Medical Holdings, Inc., dated May 5, 2021.







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


May 5, 2021By: /s/ Thomas S. Lam
 Name:   Thomas S. Lam, M.D., M.P.H.
 Title:Co-Chief Executive Officer and President